跳至主要内容
临床试验/NCT01138878
NCT01138878已完成不适用

HIV Testing in Non-traditional Settings Study

Chelsea and Westminster NHS Foundation Trust4 个研究点 分布在 1 个国家目标入组 6,350 人开始时间: 2009年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
6,350
试验地点
4
主要终点
(1) Feasibility of delivering opt-out HIV testing in ED/ACU/OPD/Primary Care setting

研究概览

简要总结

Surveillance data suggests that approximately one third of the 82 000 HIV infected adults in the UK remain undiagnosed - that is, they are living with the infection but do not know this. The majority of HIV testing in the UK to date has taken place in sexual health clinics and in antenatal care. Published National guidelines advocate routine HIV testing of 16-65 year olds in more general healthcare settings in parts of the country with relatively high rates of HIV (more than 2 per thousand individuals diagnosed locally). The HINTS Study investigates the utility, feasibility and acceptability, to patients and staff, of offering routine HIV testing in four general medical settings, all set in areas of high HIV prevalence. The settings comprise: Primary Care, Outpatients, an Acute Care Unit and an Emergency Department.

研究设计

研究类型
Observational
时间视角
Cross Sectional

入排标准

年龄范围
16 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • known HIV positive
  • unable to provide adequate contact details
  • unable to provide consent (to HIV test and/or participation in questionnaire/focus group/semi-structured interview studies)

结局指标

主要结局

(1) Feasibility of delivering opt-out HIV testing in ED/ACU/OPD/Primary Care setting

时间窗: At end of twelve week testing period at each site

次要结局

  • (2) Estimate of prevalence of undiagnosed HIV with risk factor/demographic assessment(At end of twelve week testing period)

研究者

发起方
Chelsea and Westminster NHS Foundation Trust
申办方类型
Other

研究点 (4)

Loading locations...

相似试验

已完成
不适用
Evaluation of apolipoprotein A2 isoforms and discovery of disease biomarkers by multi-omics study in population of medical checkupspancreatic cancer
JPRN-UMIN000025857Division of gastroenterology, Department of internal medicine, Kobe university Graduate school of medicine5,120
终止
不适用
SARS-CoV-2 OTC At Home TestCOVID-19 Pandemic
NCT055539643EO Health64
进行中(未招募)
1 期
Estudio fase III internacional randomizado, doble ciego, con grupos de tratamiento paralelos para evaluar la seguridad y eficacia de ocrelizumab comparado con placebo en pacientes con artritis reumatoide activa en tratamiento con metotrexato. - NAArtritis Reumatoide
EUCTR2006-005147-28-ESF. Hoffmann-La Roche Ltd1,000
已完成
3 期
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal InfectioComplicated Intra-abdominal Infection
JPRN-jRCT2061210026Kawai Norisuke60
进行中(未招募)
1 期
Estudio de fase III, randomizado, abierto, para comparar la farmacocinética, eficacia y seguridad de trastuzumab por vía subcutánea (SC) con trastuzumab por vía intravenosa (IV) administrado a mujeres con cáncer de mama precoz (CMP) HER2 positivo.Cáncer de mama localmente avanzado, inflamatorio o en estadio inicial HER2 positivoMedDRA version: 9.1Level: LLTClassification code 10006194Term: Breast cancer NOS stage IMedDRA version: 9.1Level: LLTClassification code 10006195Term: Breast cancer NOS stage IIMedDRA version: 9.1Level: LLTClassification code 10006196Term: Breast cancer NOS stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancer
EUCTR2008-007326-19-ESF. Hoffmann-La Roche Ltd552